A new analysis in the British Journal of Cancer reports that the timing of immune checkpoint inhibitor dosing can influence overall survival in advanced cancer, based on a large single-center cohort. The study shifts focus from whether immunotherapy works to how its administration timing may shape outcomes. Rather than evaluating only treatment efficacy, the work examines survival in relation to when patients receive therapy. The implication for oncology operations is that scheduling practices and time-to-initiation may be clinically meaningful variables. For clinicians and trial designers, the result adds a layer of complexity to protocol standardization and real-world treatment sequencing, especially when patient baseline characteristics or clinical stabilization intervals vary.